Login to Your Account



Opsumit Talks: Mulling Future of Latest Entry in PAH Therapy

By Randy Osborne
Staff Writer

Monday, October 21, 2013
“Best case scenario” was the phrase flying around after last week’s approval of Actelion Ltd.’s Opsumit (macitentan), the next-generation dual endothelin receptor antagonist (ERA) for pulmonary arterial hypertension. Approval of the Allschwil, Switzerland-based firm’s oral therapy, given once daily as a 10-mg dose to delay progression of PAH, came about a year after the filing of the new drug application.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription